BUD31 Homolog (BUD31) Peptid
BUD31
WB
-
- Target Alle BUD31 Produkte
- BUD31 (BUD31 Homolog (BUD31))
- Applikation
- Western Blotting (WB)
-
-
- Applikationshinweise
- For use with EDG-2 (CT) polyclonal antibody ABIN187787. Incubate antibody neat with at least a 50 fold stoichiometric excess of blocking peptide at 37°C for 20 min. (molecular weights of peptide and antibody are ~2.5 kDa and ~160 kDa, respectively). Antibody can then be diluted to a concentration suitable for Western blot.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- 50 µg provided in PBS at 1 mg/ml.
- Lagerung
- -20 °C
-
- Target
- BUD31 (BUD31 Homolog (BUD31))
- Hintergrund
- Blocking peptide for use in Western blotting with anti-EDG-2 (CT) (ABIN187787). Endothelial cell differentiation gene-2 (EDG-2) receptor is a high affinity receptor for lysophosphatidic acid (LPA). EDG-2, also known as lysopholipid receptor A1, Vzg-1, mrec1.3 or GPCR26, like all other EDG receptors, couple multiple (3 or more) types of G proteins and transduce decreases in c[AMP]i through Gi and increases in [Ca 2+ ]i by augmenting phos- pholipase C through Gq/11 and beta/gamma dimmers and by induction of PI3 kinase, p125 FAK, phospholipase D by activating rho through G12/13. Human EDG-2 is present in high levels on oligodendrocytes and certain human malignant T cell lines. EDG-2 receptors (with EDG-4) may play a role in protecting cardiomyocytes from apoptosis induced by hypoxia and andrenergic stimulation.
-
Sie sind hier:
